Skip to content

Study · Randomized controlled trial · 2017

2 results

Role of Weekly Teriparatide Administration in Osseous Union Enhancement within Six Months After Posterior or Transforaminal Lumbar Interbody Fusion for Osteoporosis-Associated Lumbar Degenerative Disorders: A Multicenter, Prospective Randomized Study.

Ebata S, Takahashi J, Hasegawa T, Mukaiyama K, Isogai Y, Ohba T, Shibata Y, Ojima T, Yamagata Z, Matsuyama Y, Haro H

The Journal of bone and joint surgery. American volume1 Mar 2017Cited by 120 (Europe PMC)

PMID28244906 (opens in a new tab)DOI10.2106/jbjs.16.00230 (opens in a new tab)PepBankPUB-28244906
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women after lumbar fusion, weekly teriparatide increased bone fusion versus control in the age-adjusted modified intention-to-treat analysis.

    In plain wordsIn women after lumbar fusion, weekly teriparatide increased bone fusion versus control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone fusion at four months
    Study

    n: not reported in source

    Comparator
    No teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 4 months postoperatively, bone fusion in the 2 center CT slices was significantly higher in the teriparatide arm compared with the control arm in the age-adjusted modified intention-to-treat analysis and was significantly higher at 6 months in the per-protocol analysis.
    2 context sentences
    Summary · context
    Patients were females who were ≥50 years of age, had a bone mineral density (BMD) of <80% of the sex-matched young adult mean and/or previous spinal compression or femoral fractures, and had lumbar degenerative disease.
    Summary · context
    Patients were randomly allocated to receive either weekly teriparatide, administered subcutaneously starting at week 1, for 6 months postoperatively (the teriparatide arm), or no teriparatide (the control arm).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women after lumbar fusion, weekly teriparatide increased bone fusion versus control in the per-protocol analysis.

    In plain wordsIn women after lumbar fusion, weekly teriparatide increased bone fusion versus control in the per-protocol analysis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone fusion at six months
    Study

    n: not reported in source

    Comparator
    No teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 4 months postoperatively, bone fusion in the 2 center CT slices was significantly higher in the teriparatide arm compared with the control arm in the age-adjusted modified intention-to-treat analysis and was significantly higher at 6 months in the per-protocol analysis.
    2 context sentences
    Summary · context
    Patients were females who were ≥50 years of age, had a bone mineral density (BMD) of <80% of the sex-matched young adult mean and/or previous spinal compression or femoral fractures, and had lumbar degenerative disease.
    Summary · context
    Patients were randomly allocated to receive either weekly teriparatide, administered subcutaneously starting at week 1, for 6 months postoperatively (the teriparatide arm), or no teriparatide (the control arm).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT04473989

Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture

Peking University Third Hospitaln = 80est. 1 Jun 2021 to est. 1 Jun 2024

Colles' Fracture

Trial pageClinicalTrials.govUpdated 16 Jul 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.